8-hydroxy-6H-[1,6]naphthyridin-5-one | 679797-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 8-hydroxy-6H-[1,6]naphthyridin-5-one
• 英文别名: 8-Hydroxy-6H-[1,6]naphthyridin-5-on；8-hydroxy-6H-[1,6]naphthyrin-5-one；8-hydroxy-6H-1,6-naphthyridin-5-one
• CAS: 679797-45-6
• 化学式: C₈H₆N₂O₂
• 分子量: 162.148
• InChiKey: FQOKBUIMGLAWJV-UHFFFAOYSA-N

物化性质

• 熔点：
  >310 °C
• 沸点：
  494.5±45.0 °C(Predicted)
• 密度：
  1.470±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  62.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  8-hydroxy-6H-[1,6]naphthyridin-5-one 在 三氯氧磷 作用下， 生成 5-chloro-[1,6]naphthyridin-8-ol
  参考文献：
  名称：

  Ochiai; Miyaki, Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1938, vol. 58, p. 764,768; dtsch. Ref. S. 207, 210

  摘要：

  DOI：
• 作为产物：
  描述：

  8-hydroxy-1,6-naphthyridin-5(6H)-one-7-carboxylic acid methyl ester 生成 8-hydroxy-6H-[1,6]naphthyridin-5-one
  参考文献：
  名称：

  [EN] NEUROLOGICALLY-ACTIVE COMPOUNDS
  [FR] COMPOSÉS NEUROLOGIQUEMENT ACTIFS

  摘要：

  本发明涉及具有两个融合的6元环，其中第1位置有一个氮原子，第8位置有一个羟基或巯基基团的神经活性化合物，其中至少一个环是芳香环。还公开了制备这些化合物的方法以及它们作为药物或兽药剂的用途，特别是用于治疗神经系统疾病，更具体地说是神经退行性疾病，如阿尔茨海默病。

  公开号：

  WO2004031161A1

文献信息

• Aza-and polyaza-naphthalenly ketones useful as hiv integrase inhibitors
  申请人：Zhuang Linghang

  公开号：US20050010048A1

  公开（公告）日：2005-01-13

  Certain aza- and polyaza-naphthalenyl ketones including certain quinolinyl and naphthyridinyl ketones are described as inhibitors of HIV integrase and inhibitors of HIV replication. These compounds are useful in the prevention or treatment of infection by HIV and the treatment or the delay in the onset of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  某些氮杂萘基酮和多氮杂萘基酮，包括某些喹啉基和萘啉基酮，被描述为HIV整合酶的抑制剂和HIV复制的抑制剂。这些化合物在预防或治疗HIV感染以及治疗或延缓艾滋病发作方面是有用的，可以作为化合物或药学上可接受的盐，或作为药物组合物中的成分，可选地与其他抗病毒药物、免疫调节剂、抗生素或疫苗结合使用。还描述了治疗或延缓艾滋病发作的方法以及预防或治疗HIV感染的方法。
• [EN] NEUROLOGICALLY-ACTIVE COMPOUNDS<br/>[FR] COMPOSÉS NEUROLOGIQUEMENT ACTIFS
  申请人：PRANA BIOTECHNOLOGY LTD

  公开号：WO2004031161A1

  公开（公告）日：2004-04-15

  The present invention relates to neurologically-active compounds, being heterocyclic compounds having two fused 6-membered rings with a nitrogen atom at position 1 and a hydroxy or mercapto group at position 8 with at least one ring being aromatic. Also disclosed are processes for the preparation of these compounds and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

  本发明涉及具有两个融合的6元环，其中第1位置有一个氮原子，第8位置有一个羟基或巯基基团的神经活性化合物，其中至少一个环是芳香环。还公开了制备这些化合物的方法以及它们作为药物或兽药剂的用途，特别是用于治疗神经系统疾病，更具体地说是神经退行性疾病，如阿尔茨海默病。
• Neurologically-active compounds
  申请人：Barnham Jeffrey Kevin

  公开号：US20060167000A1

  公开（公告）日：2006-07-27

  The present invention relates to neurologically-active compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

  本发明涉及神经活性化合物，其制备过程及其作为制药或兽医剂的用途，特别是用于治疗神经病症，更具体地说是神经退行性疾病，如阿尔茨海默病。
• NEUROLOGICALLY ACTIVE COMPOUNDS
  申请人：Barnham Kevin Jeffrey

  公开号：US20100160346A1

  公开（公告）日：2010-06-24

  The present invention relates to neurologically-active compounds, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of neurological conditions, more specifically neurodegenerative conditions such as Alzheimer's disease.

  本发明涉及神经活性化合物，其制备方法以及它们作为制药或兽医制剂的用途，特别是用于治疗神经系统疾病，更具体地说是神经退行性疾病，如阿尔茨海默病。
• Method of treatment of age-related macular degeneration (AMD)
  申请人：Prana Biotechnology Ltd

  公开号：EP2514423A2

  公开（公告）日：2012-10-24

  The present invention relates generally to the field of treatment and prophylaxis of retinal degenerative diseases. More particularly, the present invention contemplates a method for preventing, reducing the risk of development of, or otherwise treating or ameliorating the symptoms of, age-related macular degeneration (AMD) or related retinal conditions in mammals and in particular humans. The present invention further provides therapeutic compositions enabling dose-dependent or dose-specific administration of agents useful in the treatment and prophylaxis of age-related macular degeneration or related retinal degenerative conditions.

  本发明一般涉及视网膜变性疾病的治疗和预防领域。更具体地说，本发明考虑了一种方法，用于预防、降低哺乳动物，尤其是人类的老年性黄斑变性（AMD）或相关视网膜疾病的发病风险，或以其他方式治疗或改善其症状。本发明进一步提供了治疗组合物，可根据剂量或剂量特异性给药，用于治疗和预防老年性黄斑变性或相关视网膜退行性病变。